Use of methotrexate in ANCA-associated vasculitides

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Reinhold Keller, E ^a   De Groot, K ^b  

^a Internistisch rheumatologische Gemeinschaftspraxis   (Germany)

^b Klinikum Offenbach GmbH   (Germany)

Author keywords

ANCA associated vasculitides; Methotrexate

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; FOLIC ACID; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CHURG STRAUSS SYNDROME; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION TEST; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE SEDIMENT; WEGENER GRANULOMATOSIS; ABSENCE OF SIDE EFFECTS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; KIDNEY FAILURE; MICROSCOPIC POLYANGIITIS; MULTICENTER STUDY (TOPIC); OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHURG-STRAUSS SYNDROME; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS;

EID: 78650557651     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. HERLYN K, HELLMICH B, GROSS WL, REINHOLD-KELLER E: Stable incidence of systemic vasculitides in Schleswig-Holstein, Germany. Dtsch Arztebl Int 2008;105:355-61.
2. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
3. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
4. CAPIZZI RL, BERTINO JR: Methotrexate therapy of Wegener's granulomatosis. Ann Intern Med 1971;74:74-9.
5. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
6. METZLER C, HELLMICH B, GAUSE A, GROSS WL, DE GROOT K: Churg Strauss syndromesuccessful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004;22(Suppl. 36): S52-61.
7. HOFFMAN GS, LEAVITT RY, KERR GS, FAUCI AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
8. SNELLER MC, HOFFMAN GS, TALAR-WILLIAMS C, KERR GS, HALLAHAN CW, FAUCI AS: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608-13.
9. LANGFORD CA, TALAR-WILLIAMS C, SNELLER MC: Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000;43:1836-40.
10. DE GROOT K, MUHLER M, REINHOLD-KELLER E, PAULSEN J, GROSS WL: Induction of remission in Wegener's granulomatosis with low-dose methotrexate. J Rheumatol 1998;25:492-5.
11. STONE JH, TUN W, HELLMAN DB: Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999;26:1134-9.
12. VILLA-FORTE A, CLARK TM, GOMES M et al.: Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007;86:269-77.
13. WGET RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
14. HOLLE J, GROSS WL, LATZA U et al.: Improved outcome of 445 Wegener's granulomatosis patients in a German vasculitis center over four decades. Arthritis Rheum (in revision) 2010.
15. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
16. DE GROOT K, REINHOLD-KELLER E, TATSIS E, PAULSEN J, HELLER M, GROSS WL: Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus Trimethoprim/Sulfamethoxazole. Arthritis Rheum 1996;39:2052-61.
17. LANGFORD CA, TALAR-WILLIAMS C, BARRON KS, SNELLER MC: A staged approach to the treatment of Wegener's granulomatosis. Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666-73.
18. LANGFORD CA, TALAR-WILLIAMS C, BARRON KS, SNELLER MC: Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9.
19. REINHOLD-KELLER E, FINK CO, HERLYN K, GROSS WL, DE GROOT K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002 Jun. 15; 47:326-32.
20. METZLER C, MIEHLE N, MANGER K et al.: Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007;46:1087-91.
21. PAGNOUX C, MAHR A, HAMIDOU MA et al.: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803.
22. PAGNOUX C, HOGAN SL, CHIN H et al.: Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum 2008;58:2908-18.
23. FINKIELMAN JD, MERKEL PA, SCHROEDER D et al.: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611-9.
24. FLOSSMANN O, DE GROOT K: When should patients with ANCA-associated vasculitis be switched from induction to maintenance therapy? Nat Clin Pract Nephrol 2007;3:236-7.
25. WALSH M, MERKEL PA, MAHR A, JAYNE D: The effects of duration of glucocorticoid therapy on relapse rate in anti-neutrophil cytoplasm antibody associated vasculitis: A meta-analysis. Arthritis Care Res 2010, 62:1166-73.